Table 2.
Antibody-based treatments reported to augment NK cell activity.
| Treatment | Key elements | Current stage of development | |
|---|---|---|---|
| Pre-clinical | Clinical trials | ||
| 293C3-SDIE | Optimized anti-CD133 (high expression on colorectal cancer) antibody containing S239D and I332E amino acid substitutions, increasing affinity for CD16. | ✓ (176) |
|
| VAY736 | Optimized anti-BAFF-R (highly expressed on B-ALL) antibody. | NCT03400176 | |
| CSL362/ Talacotuzumab | Humanized anti-CD123 monoclonal antibody (high expression on Hodgkin lymphoma) with increased affinity for CD16. | NCT03011034 | |
| B12 | Anti-IL-7 receptor antibody (IL-7 promotes leukemia development and chemotherapy resistance). Demonstrates rapid internalization and lysosome trafficking. | ✓ (177) |
|
| MEN1112 | Anti-CD157 antibody (high expression on primary AML cells). | NCT02353143 | |
| 7C6 mAb | Monoclonal antibody directed against MICA α3 domain, preventing proteolytic shedding of MICA/MICB from tumors. | ✓ (178) |
|
| Elotuzumab | Antibody against SLAMF7 (high expression on multiple myeloma). | 28 active/recruiting clinical trials as of February 2020 (www.clinicaltrials.gov) | |
| F1 | Antibody against the aspartic protease cathepsin D (high production and secretion by breast cancer cells). | ✓ (179) |
|
| hu14.18K322A | Anti-GD2 antibody (high expression on neuroblasts). | NCT02159443, NCT01857934 | |
| Codrituzumab | Antibody targeting oncofetal protein glypican-3 (high expression on hepatocellular carcinoma). | NCT01507168 (completed phase II) | |
| BI 836858 | Anti-CD33 antibody (high expression on AML cells). | NCT02240706, NCT02632721 | |